Literature DB >> 11444762

Methodology to measure onset of action.

M E Thase1.   

Abstract

Onset of action has become one of the most topical issues in antidepressant therapy. In general, the speed of onset of action of antidepressants is regarded as too slow. Most patients who benefit from treatment require 2 or more weeks of therapy to show signs of response. Since the onset of therapeutic efficacy is of current interest to physicians and health authorities, the question arises of how to measure the onset of therapeutic efficacy. There are many different proposals for the statistical analysis of data to determine early onset of action. One of the most important considerations in analyzing early onset of action is the definition of criteria. Conventional approaches, such as the De Paula and Omer approach and the Huitfeldt and Montgomery approach, can provide useful information, although they do not take into account whether the early response is sustained. The use of pattern analyses does overcome the problem, but the generalizability of their findings is somewhat limited by their use of stringent exclusion criteria. Survival analyses can provide a more sensitive measure of early changes. Moreover, this method can easily be adapted to take into account sustained response and be used to restrict attention only to those subjects who achieve onset. In this article, the above-mentioned approaches will be explained with the help of some clinical examples to achieve a further understanding of the methodology of measuring onset of action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444762

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine.

Authors:  Heidi K Moore; Madelaine M Wohlreich; Michael G Wilson; James C Mundt; Maurizio Fava; Craig H Mallinckrodt; John H Greist
Journal:  Psychiatry (Edgmont)       Date:  2007-03

Review 2.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

Review 3.  Time course of response to antidepressants in late-life major depression: therapeutic implications.

Authors:  Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Efficacy and safety of add on low-dose mirtazapine in depression.

Authors:  Prithpal S Matreja; Dinesh K Badyal; Randhir S Deswal; Arvind Sharma
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

5.  Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study.

Authors:  Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Donald P Hay
Journal:  BMC Geriatr       Date:  2004-12-07       Impact factor: 3.921

Review 6.  Atypical antipsychotics in the treatment of early-onset schizophrenia.

Authors:  Michal Hrdlicka; Iva Dudova
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-01       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.